TRX 1 - Tolerx

Drug Profile

TRX 1 - Tolerx

Alternative Names: Anti-CD4 monoclonal antibody - Tolerx; MTRX 1011A; RG 7424; TRX1 - Tolerx

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Oxford
  • Developer Genentech; Tolerx
  • Class Monoclonal antibodies
  • Mechanism of Action CD4 antigen inhibitors; CD45 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Autoimmune disorders; Cutaneous lupus erythematosus; Rheumatoid arthritis

Most Recent Events

  • 07 Oct 2011 Discontinued - Phase-I for Autoimmune disorders in United Kingdom (Parenteral)
  • 07 Oct 2011 Discontinued - Phase-I for Cutaneous lupus erythematosus in USA (Parenteral)
  • 05 Aug 2008 Genentech initiates enrolment in a phase I trial of MTRX1011A (a modified version of TRX 1) in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top